OneSource, Hikma get approval for generic Ozempic in Saudi Arabia

OneSource Specialty Pharma has received Saudi Food and Drug Authority (SFDA) approval for its generic Ozempic (semaglutide) in Saudi Arabia, paving the way for its commercialisation with Hikma Pharmaceuticals PLC (Hikma), their exclusive partner for the Middle East and North Africa (MENA), the company said.The approval marks OneSource’s entry—a contract development and manufacturing organisation—into Saudi Arabia, one of the largest markets for GLP-1 therapies. The partnership aims to increase access to aff ...